Development of enhanced HIV-1 non-nucleoside reverse transcriptase inhibitors with improved resistance and pharmacokinetic profiles
Science Advances · 2025
DOI: 10.1126/sciadv.adt8916 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Zhao Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of …. Hauptthemen laut MEDLINE: Reverse Transcriptase Inhibitors, HIV-1, Drug Resistance, Viral, HIV Reverse Transcriptase. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
HIV-1 infection is a manageable chronic condition, with non-nucleoside HIV-1 reverse transcriptase inhibitors (NNRTIs) remaining a cornerstone of antiretroviral therapy. Nevertheless, drug resistance to existing therapeutics is a serious and immediate concern. Using structure-based and scaffold-hopping approaches, we designed evolved diarylpyrimidine analogs targeting reverse transcriptase (RT), exploiting chemical space surrounding the NNRTI-binding pocket. We identified compounds 5i3 and 5e2 , with robust antiviral efficacy against wild-type HIV-1 and rilpivirine-resistant strains. Encouragingly, in vitro selection of mutant strains with 5i3 took 39 passages to select resistance, with no phenotypic cross-resistance observed with known RT drugs. Co-crystal structures of wild-type and mutant RT with 5i3 and 5e2 revealed their resilience toward resistance mutations due to enhanced conformational flexibility and positional adaptability. 5i3 exhibited good pharmacokinetic properties and favorable safety profiles, without substantial cytochrome P450 inhibition, and excellent oral bioavailability. These derivatives represent a promising scaffold for the development of anti-HIV drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, PR China.
- China-Belgium Collaborative Research Center for Innovative Antiviral Drugs of Shandong Province, Jinan 250012, Shandong, PR China.
- Center for Advanced Biotechnology and Medicine, and Department of Chemistry and Chemical Biology, Rutgers University, Piscataway, NJ 08854, USA.
- Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, K.U. Leuven, Herestraat 49 Postbus 1043 (09.A097), B-3000 Leuven, Belgium.
- Surgical Oncology Research Facility, Duke University Medical Center, Box 2926, Durham, NC 27710, USA.
ORCID-Profile: Zhao Wang, Shawn Rumrill, Dongwei Kang, Samuel Desta Guma, Erik De Clercq, Christophe Pannecouque, Chin Ho Chen, Eddy Arnold, Francesc Xavier Ruiz, Xinyong Liu, Peng Zhan
Förderung
- NIAID NIH HHS
Zitieren
APA
Wang, Z., Rumrill, S., Kang, D., Guma, S. D., Feng, D., De Clercq, E., Pannecouque, C., Chen, C. H., Arnold, E., Ruiz, F. X., Liu, X., & Zhan, P. (2025). Development of enhanced HIV-1 non-nucleoside reverse transcriptase inhibitors with improved resistance and pharmacokinetic profiles. Science Advances. https://doi.org/10.1126/sciadv.adt8916
Vancouver
Wang Z, Rumrill S, Kang D, Guma SD, Feng D, De Clercq E, et al. Development of enhanced HIV-1 non-nucleoside reverse transcriptase inhibitors with improved resistance and pharmacokinetic profiles. Science Advances. 2025. doi:10.1126/sciadv.adt8916
BibTeX
@article{Wang2025,
author = {Wang, Zhao and Rumrill, Shawn and Kang, Dongwei and Guma, Samuel Desta and Feng, Da and De Clercq, Erik and Pannecouque, Christophe and Chen, Chin Ho and Arnold, Eddy and Ruiz, Francesc Xavier and Liu, Xinyong and Zhan, Peng},
title = {Development of enhanced HIV-1 non-nucleoside reverse transcriptase inhibitors with improved resistance and pharmacokinetic profiles},
journal = {Science Advances},
year = {2025},
doi = {10.1126/sciadv.adt8916}
}
EUVIMED